Abstract Details

Title Cross-validation of the Orthostatic Tremor Severity and Disability Scale (OT-10)

Topic Movement Disorders

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 17-008

Objective We aimed to cross-validate the Orthostatic Tremor Severity and Disability Scale (OT-10) by comparing it to four different assessments: the Activities-specific Balance Confidence Scale (ABC), Dizziness Handicap Inventory (DHI), Short Form Health Survey (SF-36), and the Clinical Global Impression Scale of Severity (CGI-S).

Background Orthostatic Tremor (OT) is a rare and debilitating movement disorder characterized by 13-18 Hz leg tremors and unsteadiness upon standing that alleviates when walking or sitting. The OT-10 scale was created in 2020 to objectively assess symptom severity in OT patients, and to be used as possible studies end-point. However, the scale has not undergone convergence validation.

Design/Methods Data collected prospectively and simultaneously from 16 OT patients (12 female) for all five scales. Mean age 70 years (48-80 yrs). Mean disease duration 19 years (5-60 yrs). Final scores from the OT-10 were compared to the ABC, DHI, SF-36, and CGI-S scores using correlation and regression analysis to determine the relationship and similarity between the scales. Correlations were calculated using a Pearson Correlation Test.

Results The ABC, DHI, SF-36, and CGI-S were found to strongly predict the OT-10 scores (R² = 0.7, F(4) = 7.86, p = 0.003). The OT-10 has a strong significant relationship with the ABC (r = -0.72, p = 0.002) and the CGI-S (r = 0.51, p = 0.04), but has nonsignificant relationships with the DHI (r = -0.34, p = 0.198) and SF-36 (r = -0.40, p = 0.182). We further discuss the likely explanations of these relationships, in particular as it relates to balance specificity.

Conclusions Our study provides convergence validation data for the use of the OT-10 scale. Future studies should focus on the development and validation of translated versions of the scale.

Authors/Disclosures
David M. Whitney, MD PRESENTER	Dr. Whitney has nothing to disclose.
Kayleigh A. McLaughlin	Miss McLaughlin has nothing to disclose.
Erin Smith, MD (University of Nebraska Medical Center)	Dr. Smith has nothing to disclose.
Starlie C. Belnap, PhD	Dr. Belnap has nothing to disclose.
Sofia Torres-Salvador	Ms. Torres-Salvador has nothing to disclose.
Kiel Woodward, MD (UNMC)	Dr. Woodward has nothing to disclose.
Laura Torres-Salvador	Miss Torres-Salvador has nothing to disclose.
Danish Bhatti, MD, FAAN (University of Central Florida College of Medicine)	Dr. Bhatti has nothing to disclose.
Amy Hellman, MD, FAAN (University of Nebraska Medical Center)	The institution of Dr. Hellman has received research support from COBRE-NIH. The institution of Dr. Hellman has received research support from Neurocrine.
Diego Torres-Russotto, MD, FAAN (Miami Neuroscience Institute - Baptist Health South Florida)	Dr. Torres-Russotto has received personal compensation for serving as an employee of Movement Disorders Consulting, Inc. The institution of Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acorda. The institution of Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. The institution of Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. The institution of Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Revance. The institution of Dr. Torres-Russotto has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anneal. Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acorda. Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for IPSEN. Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Torres-Russotto has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie. The institution of Dr. Torres-Russotto has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurocrine. Dr. Torres-Russotto has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Your Nest Asset Solutions, LLC. Dr. Torres-Russotto has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Bright Future Asset Solutions, LLC.

��ɫ��

��ɫ��